Alteogen reports 140.5 billion won first-half revenue

The Tip Desk · August 14, 2026 · 2 min read

The biotech firm recorded 116.4 billion won from ALT-B4 technical services in the first half of 2026.

The biotech developer Alteogen recorded consolidated revenue of 140.49 billion won for the first half of 2026. Technical service revenue from the ALT-B4 project led the results, contributing 116.36 billion won, which represented 82.8% of total revenue. This specific stream included milestone payments, upfront fees, and the supply of clinical samples following license-out agreements for hyaluronidase technology.

Revenue from the ALT-L9 project rose to 11.52 billion won, accounting for 8.2% of the total. This growth followed the South Korean Ministry of Food and Drug Safety approval of EYZANFY in May 2026 and the European Medicines Agency approval of Eyluxvi in September 2025. The company recognizes revenue from ALT-L9 based on sales license agreements and milestones after obtaining product licenses.

Alteogen expanded its partnership network through several exclusive license agreements for ALT-B4. These included deals with AstraZeneca subsidiaries MedImmune LLC and MedImmune Limited in March 2025, and a deal with GSK subsidiary Tesaro Inc. in January 2026. Additionally, the company signed a license agreement for the development and commercialization of subcutaneous formulation biopharmaceuticals with Biogen International GMBH in May 2026.

Product sales fell to 382.63 million won in the first half of 2026, down from 28.13 billion won in 2025. The company provides commercialized products to license partners and records these as product revenue.

Subsidiary Alteogen Biologics showed a shift in financial performance. The subsidiary reported revenue of 20.49 billion won and a net profit of 6.30 billion won for the current half-year period. This follows a previous half-year period where the subsidiary recorded revenue of 6.64 billion won and a net loss of 5.87 billion won.

Alteogen is planning to build production facilities for commercial products and clinical samples on land it has already purchased. The company also maintains a capital expenditure commitment of 3.75 billion won related to the relocation of its headquarters.